Benign Prostatic Hyperplasia

Oncology·MeSH: Prostatic Hyperplasia

Prevalence

1564.6 / 100K

Incidence

190.6 / 100K/yr

6 drugs in development·6 companies·3 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
aquablation therapy	PROCEPT BioRobotics Corporation (PRCT)
Cialis®	ELI LILLY & Co (LLY)
entadfi	Onconetix, Inc. (ONCO)
tulsa-pro	Profound Medical Corp. (PROF)

Phase 3(1)

Drug	Company
alpha blocker and 5-alpha reductase inhibitor	Merus N.V. (MRUS)

Phase 4(1)

Drug	Company
Intravesical Botox injection	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 6 drugs in development for Benign Prostatic Hyperplasia across 6 companies.

There are 3 clinical trials targeting Benign Prostatic Hyperplasia tracked by BioSniper.

The estimated prevalence of Benign Prostatic Hyperplasia is approximately 1564.6 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.